James Malone

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes
    P Roach
    Indiana University School of Medicine and Eli Lilly and Company, Indianapolis, IN 46202, USA
    Diabet Med 23:743-9. 2006
  2. ncbi request reprint Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?
    James K Malone
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Diabetes Res Clin Pract 62:187-95. 2003
  3. ncbi request reprint Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes
    J K Malone
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Diabet Med 22:374-81. 2005
  4. ncbi request reprint Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy
    James K Malone
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Clin Ther 26:2034-44. 2004
  5. ncbi request reprint Exenatide once weekly for the treatment of type 2 diabetes
    James Malone
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Expert Opin Investig Drugs 18:359-67. 2009
  6. pmc Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
    Anne Gill
    Eli Lilly and Company, Indianapolis, USA
    Cardiovasc Diabetol 9:6. 2010
  7. ncbi request reprint A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan
    V Mattoo
    Eli Lilly and Company, Indianapolis, IN, USA
    Diabetes Res Clin Pract 59:137-43. 2003
  8. ncbi request reprint Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison
    Liza L Ilag
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Ther 29:1254-70. 2007

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes
    P Roach
    Indiana University School of Medicine and Eli Lilly and Company, Indianapolis, IN 46202, USA
    Diabet Med 23:743-9. 2006
    ....
  2. ncbi request reprint Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?
    James K Malone
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Diabetes Res Clin Pract 62:187-95. 2003
    ....
  3. ncbi request reprint Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes
    J K Malone
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Diabet Med 22:374-81. 2005
    ....
  4. ncbi request reprint Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy
    James K Malone
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Clin Ther 26:2034-44. 2004
    ....
  5. ncbi request reprint Exenatide once weekly for the treatment of type 2 diabetes
    James Malone
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Expert Opin Investig Drugs 18:359-67. 2009
    ..Given the rapidly increasing prevalence of diabetes and obesity worldwide, exenatide QW is a promising development candidate for the treatment of T2DM...
  6. pmc Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
    Anne Gill
    Eli Lilly and Company, Indianapolis, USA
    Cardiovasc Diabetol 9:6. 2010
    ..Our aim was to assess the effects of the glucagon-like peptide-1 receptor agonist exenatide on heart rate (HR) and blood pressure (BP) in subjects with type 2 diabetes mellitus (T2DM)...
  7. ncbi request reprint A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan
    V Mattoo
    Eli Lilly and Company, Indianapolis, IN, USA
    Diabetes Res Clin Pract 59:137-43. 2003
    ....
  8. ncbi request reprint Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison
    Liza L Ilag
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Ther 29:1254-70. 2007
    ..When glycemic goals are not achieved with the initial insulin regimen, a basal-bolus regimen is necessary...